HomeNDC LookupRxCUI directory › RxCUI 2670166

Crizotinib 150 MG Oral Pellet — RxCUI 2670166

RxNorm drug concept · Semantic clinical drug
RxCUI 2670166 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2670166
Official nameCrizotinib 150 MG Oral Pellet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)130 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Crizotinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Crizotinib (Xalkori) targets cancers that carry specific gene changes — called ALK or ROS1 alterations — that drive tumor growth. It's approved for certain adults with metastatic n...
  • What exactly does crizotinib treat, and how do I know if it's right for me?
  • You can take Xalkori capsules with or without food — it's flexible. A high-fat meal does slightly reduce how much gets absorbed, but the effect is modest and the label allows eithe...
  • Does it matter if I take Xalkori with food or on an empty stomach?
📖 Read our full Crizotinib guide →

🕸️ Concept Web — How Crizotinib 150 MG Oral Pellet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Crizotinib 150 MG Oral Pellet RxCUI 2670166

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Crizotinib 1148495
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Xalkori 1148499
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Crizotinib Oral Pellet 2670165
    • Crizotinib Oral Product 1165616
    • Crizotinib Pellet Product 2670164
    • Crizotinib Oral Pellet [Xalkori] 2670169
    • Xalkori Oral Product 1186298
    • Xalkori Pellet Product 2670168
    • Oral Pellet 317691
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Crizotinib 150 MG SCDC · 2670163
  • Crizotinib Oral Pellet SCDF · 2670165
  • Crizotinib Oral Product SCDG · 1165616
  • Crizotinib Pellet Product SCDG · 2670164

Brand-Name Concepts

  • Crizotinib 150 MG Oral Pellet [Xalkori] SBD · 2670170
  • Crizotinib 150 MG [Xalkori] SBDC · 2670167
  • Crizotinib Oral Pellet [Xalkori] SBDF · 2670169
  • Xalkori Oral Product SBDG · 1186298
  • Xalkori Pellet Product SBDG · 2670168
  • Xalkori BN · 1148499

📦 FDA Products & Package NDCs

5 products · 5 package NDCs
5 package NDCs map to RxCUI 2670166 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0251-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-0251-60) Xalkori Pfizer Laboratories Div Pfizer Inc 2023-11-20
00069-0507-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-0507-60) Xalkori Pfizer Laboratories Div Pfizer Inc 2023-11-20
00069-1500-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-1500-60) Xalkori Pfizer Laboratories Div Pfizer Inc 2023-11-20
00069-8140-20 60 CAPSULE in 1 BOTTLE (0069-8140-20) Xalkori Pfizer Laboratories Div Pfizer Inc 2011-08-26
00069-8141-20 60 CAPSULE in 1 BOTTLE (0069-8141-20) Xalkori Pfizer Laboratories Div Pfizer Inc 2011-08-26
Observed labelers: Pfizer Laboratories Div Pfizer Inc (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.